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Abstract
Purpose—To develop cross-linked nanoassemblies (CNAs) as carriers for superparamagnetic
iron oxide nanoparticles (IONPs).
Methods—Ferric and ferrous ions were co-precipitated inside core-shell type nanoparticles
prepared by cross-linking poly(ethylene glycol)-poly(aspartate) block copolymers to prepare
CNAs entrapping Fe3O4 IONPs (CNA-IONPs). Particle stability and biocompatibility of CNA-
IONPs were characterized in comparison to citrate-coated Fe3O4 IONPs (Citrate-IONPs).
Results—CNA-IONPs, approximately 30 nm in diameter, showed no precipitation in water,
PBS, or a cell culture medium after 3 or 30 h, at 22, 37, and 43 °C, and 1, 2.5, and 5 mg/mL,
whereas Citrate-IONPs agglomerated rapidly (> 400 nm) in all aqueous media tested. No
cytotoxicity was observed in a mouse brain endothelial-derived cell line (bEnd.3) exposed to
CNA-IONPs up to 10 mg/mL for 30 h. Citrate-IONPs (> 0.05 mg/mL) reduced cell viability after
3 h. CNA-IONPs retained the superparamagnetic properties of entrapped IONPs, enhancing T2-
weighted magnetic resonance images (MRI) at 0.02 mg/mL, and generating heat at a mild
hyperthermic level (40 ~ 42 °C) with an alternating magnetic field (AMF).
Conclusion—Compared to citric acid coating, CNAs with a cross-linked anionic core improved
particle stability and biocompatibility of IONPs, which would be beneficial for future MRI and
AMF-induced remote hyperthermia applications.
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imaging; hyperthermia
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INTRODUCTION
Iron oxide nanoparticles (IONPs) are superparamagnetic materials, which can be activated
only in the presence of an external magnetic field, enabling various bionanomedical
applications (1, 2). For example, IONPs have been used as contrast agents that can enhance
T2-weighted (signal darkening) magnetic resonance images (MRI) of tissues in vivo (3–5).
The particle sizes of IONPs can be tailored to accumulate in specific organs, contributing to
early detection of human malignancies with blood vessel disruption (6–8).
IONPs have drawn increasing attention as MRI contrast agents to evaluate blood-brain
barrier dysfunction related to tumors and other pathologies in the central nervous system
(e.g. brain tumor, stroke, and carotid atherosclerosis) in clinical and preclinical studies (9,
10). IONPs can be also used as a heating source for hyperthermia as they generate heat in
the presence of an alternating magnetic field (AMF) to increase temperature in solutions or
localized tissues, thereby killing cancer cells in a controlled manner (11–13). Hyperthermia
above 40 °C can induce tumor cell death, because tumor cells are susceptible to sudden
temperature increases (14). One major problem for conventional hyperthermia therapy is to
increase temperature to a therapeutic level in the center of the tumor (7). A clinical study
showed that hyperthermia using IONPs in conjunction with a reduced radiation dose led to
longer survival of patients compared to conventional therapies in the treatment of recurrent
glioblastoma (15). This dual functionality (i.e. T2 MRI enhancement and AMF-induced
remote heating) makes IONPs useful for novel applications combining both diagnosis and
therapy of human diseases, an application often referred to as theranostics (16, 17).
Theranostics is important particularly for the treatment of tumors in delicate organs,
susceptible to drugs, heat, or other physicochemical stress factors (e.g. the brain).
A problem with IONPs is their tendency to agglomerate in aqueous solutions unless their
surface is properly modified, resulting in plasma protein binding in vivo and rapid clearance
by the mononuclear phagocyte system (MPS) (18). Aggregation of IONPs leads to altered
magnetic properties or even complete loss of magnetism (19). In addition, IONPs are easily
oxidized, transforming from magnetite (Fe3O4) to maghemite (γFe2O3), leading to a broad
spectrum of particle size, shape, stability, and magnetic properties (20, 21). Several studies
showed that IONPs, either bare or surface-modified, could cause cell toxicity and oxidative
stress in vitro and in vivo (22–24). Therefore, it is crucial to improve particle stability and
biocompatibility of IONPs in biological environment. Numerous efforts have been made to
suppress agglomeration and retain the superparamagnetic properties of IONPs for a
prolonged time (25–27). Citric acid and surfactants are frequently used to stabilize IONPs in
aqueous solutions (28–30), but these stabilizers often cause problems. For example,
although citric acid forms a stable chelate with Fe3O4 iron oxide, it is not sufficient to
prevent agglomeration and precipitation in the presence of multivalent counter ions
(magnesium or calcium) and serum proteins (31–34). Surfactants, typically prepared from
multivalent polymers, have been also developed to stabilize IONPs in vivo, yet they can get
detached from IONPs due to an unclear mechanism by which ligand exchange occurs in
metal chelates (35–37). Importantly, these IONP formulations, which change particle
stability over time in vivo, could potentially cause toxic effects in vivo (38, 39).
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Biocompatible polymer nanoparticles and water soluble polymers have been used as less
toxic and more stable alternatives to these stabilizers (19, 20). Among these polymer-based
formulations, polymeric micelles from amphiphilic block copolymers are an attractive
choice to develop IONP formulations for cancer imaging and hyperthermia (40, 41).
Micelles can embed IONPs and achieve considerable MRI contrast enhancement as a result
of the collective effects of IONP clusters (42–44). However, one of the critical problems
associated with conventional polymeric micelles is particle stability, particularly in dilute
conditions (e.g. blood and other biological environments) as polymer micelles can dissociate
below the critical micelle concentration (45). To solve these problems, we recently
developed cross-linked nanoassemblies (CNAs) from biocompatible poly(ethylene glycol)-
poly(aspartate) [PEG-p(Asp)] block copolymers, which provided stable nanoparticles that
can entrap charged, hydrophobic, and amphiphilic payloads without changing particle sizes
optimized for tumor accumulation (< 100 nm) (46–48). We hypothesized that CNAs
containing carboxyl groups in the core would simultaneously create, entrap, and protect
IONPs as iron ions (Fe2+ and Fe3+) co-precipitate inside the nanoassembly core, thus
suppressing IONP agglomeration (Figure 1). In this study, we tested our hypothesis and
confirmed that IONPs incorporated into CNAs improve their particle stability and
biocompatibility in aqueous solutions without compromising paramagnetic properties.
Particle stability and biocompatibility were determined with or without 30 min AMF
exposure in water, phosphate buffered saline (PBS), and a cell culture medium with 10%
fetal bovine serum (FBS) at 22, 37, and 43 °C, corresponding to room, body, and
hyperthermic temperatures, respectively. Cytotoxicity of the particles was investigated using
a mouse brain endothelial-derived cell line (bEnd.3). To evaluate potential imaging
applications, T2-weighted MRI enhancement of CNA-IONPs was tested in water, PBS and a
cell culture medium. AMF-induced heating properties of 1, 2.5 and 5 mg/mL CNA-IONPs
were also evaluated in a cell culture medium for future hyperthermia applications.
Conventional citrate-coated IONPs (Citrate-IONPs) were used as control. Results of this
study provide insight into potential applications of CNA-IONPs, integrating MRI diagnosis
and thermal therapy.
MATERIALS AND METHODS
Materials
N,N′-Diisopropylcarbodiimide (DIC), N-hydroxysuccinimide (NHS), 4-
(dimethylamino)pyridine (DMAP), β-benzyl L-aspartate, triphosgene, hexane, benzene,
tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), ferrous chloride tetrahydrate
(FeCl2·4H2O), ferric chloride hexahydrate (FeCl3·6H2O), ammonium hydroxide (NH4OH),
citric acid monohydrate, and ethanol (100%) were purchased from Sigma-Aldrich (St.
Louis, MO, USA). α-Methoxy-ω-amino poly(ethylene glycol) (PEG, 5 kDa) was purchased
from the NOF Corporation (Tokyo, Japan). Cell culture medium Dulbecco's Modified Eagle
Medium (DMEM), regenerated cellulose dialysis bags with 6 ~ 8 kDa molecular weight cut
off (MWCO), sodium hydroxide (NaOH), and hydrochloric acid (HCl) were purchased from
Fisher Scientific (USA). FBS was purchased from Atlanta Biologicals (Lawrenceville, GA,
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USA) and penicillin-streptomycin (Pen-Strep) was purchased from Invitrogen (Grand
Island, NY, USA).
Synthesis of CNAs
CNAs were prepared by cross-linking poly(ethylene glycol)-poly(aspartate) [PEG-p(Asp)]
block copolymers as previously reported with slight modification (46). Briefly, β-Benzyl-L-
aspartate N-carboxy anhydride (BLA-NCA) monomers were prepared by reacting β-benzyl-
L-aspartate with triphosgene (1.3 equivalent) in dry THF at 45°C until the solution became
clear. Anhydrous hexane was added to the BLA-NCA, which was subsequently
recrystallized at −20°C. As shown in Figure 2, BLA-NCA monomers were polymerized
using amino-terminated 5kDa PEG as a macroinitiator in DMSO (50 mg/mL) at 45°C under
dry nitrogen for 48 h to synthesize PEG-poly(β-benzyl L-aspartate) (PEG-PBLA). PEG-
PBLA was collected from the reaction solution by precipitation in diethyl ether and freeze
drying from benzene. 1H-NMR (400 MHz, Varian) spectra from PEG (3.5 ppm) and benzyl
groups (7.3 ppm) was used to determine the block copolymer composition. PEG-PBLA with
40 aspartate repeating units was used for this study. The benzyl groups of PEG-PBLA were
removed by 0.1 N NaOH. The benzyl alcohol byproducts and excess NaOH were removed
through dialysis, followed by desalination of the aspartate through the addition of HCl to the
dialysis solution to yield PEG-p(Asp). To prepare CNAs, PEG-p(Asp) was dissolved in
DMSO to a final concentration of 75 mg/mL followed by the addition of DIC, NHS, and
DMAP (in a molar ratio of 4:4:0.2, respectively) to the aspartate units of PEG-p(Asp). A 0.5
molar equivalent of 1,8-diaminooctane was added to the reaction solution, which was placed
at 50°C for 72 h. The CNAs were dialyzed against 100% DMSO, 50% DMSO, and finally
deionized water to remove impurities, followed by freeze drying. CNA purity was
characterized with gel permeation chromatography (GPC, Shimadzu LC20, Japan), which
was equipped with refractive index (RI) and ultraviolet (UV) detectors. PEG standards were
used to establish a calibration curve for molecular weight determination (Mn = number
molecular weight).
Preparation of Citrate-IONPs and CNA-IONPs
Citrate-IONPs were prepared by co-precipitating iron oxides and citric acid in an aqueous
solution as previously reported (2). As shown in Figure 2B, ferric chloride hexahydrate
(Fe3+) and ferrous chloride tetrahydrate (Fe2+) were dissolved in deionized water (Fe3+ Fe2+
= 2:1), followed by adding ammonium hydroxide dropwise under an N2 atmosphere at 85
°C. Citric acid (2 equivalent) was then added to prepare Citrate-IONPs. After 1 h, the
solution was placed on a magnet to collect black brown particles, which were washed
repeatedly using pure ethanol (28, 49). Citrate-IONPs were dried overnight in a vacuum
drying oven.
CNA-IONPs were prepared similarly by mixing ferric and ferrous salts at a 2:1 molar ratio
with CNAs in deionized water (Figure 2C). The total iron ions and the carboxyl groups of
CNAs were adjusted in a molar ratio of 1:2. Ammonium hydroxide was added to this mixed
solution dropwise under nitrogen atmosphere and the reaction was allowed to proceed at
85°C for 1 h. The solution was centrifuged at 3,000 g for 5 min to remove precipitates and
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other water-insoluble impurities. CNA-IONPs in the supernatant were dialyzed (MWCO 6 ~
8 kDa), filtered (0.22 µm syringe filters), and collected by freeze drying.
Particle characterization
The particle size distribution was determined by dynamic light scattering (DLS) analysis
(90Plus NanoParticle size distribution analyzer, Brookhaven Instruments, Holtsville, NY,
USA). Zeta potential was measured with Zetasizer Nano ZS (Malvern Instruments,
Worcestershire, UK). The IONP loading content for CNA-IONPs was quantified by thermal
gravimetric analysis (TGA, Perkin-Elmer TGA7 Analyzer, Waltham, MA, USA) and
inductively coupled plasma mass spectrometry (ICP-MS, Agilent 7500cx, Santa Clara, CA,
USA). TGA and ICP-MS determined the amount of iron remaining from CNA-IONPs,
following thermal decomposition (100 ~ 600 °C) and chemical digestion (HNO3:H2O2 =
2:1) of CNAs, respectively.
Particle size and stability evaluation in aqueous media
Particle size and stability of Citrate-IONPs and CNA-IONPs (0.1 mg/mL, based on IONP
content) were first observed by dissolving the particles in water, PBS, and DMEM with 10%
FBS and 1% Pen-Strep, using 1.5 mL microvials. Aqueous solubility, particle size, and
stability of Citrate-IONPs and CNA-IONPs were further characterized under various media:
in water at 1 mg/mL, 22 °C, for 30 h; in water at 1 mg/mL, 37 °C, for 30 h; in cell culture
medium at 1 mg/mL, 37 °C, for 30 h; and in cell culture medium at 1 mg/mL, 43 °C, for 30
h, as discussed in detail in the Results and Discussion section. DLS was used to monitor
time-dependent changes in particle size of all samples.
Cytotoxicity assays
A mouse brain endothelial cell line (bEnd.3) was obtained from American Type Culture
Collection (CRL-2299). The cells were cultured in a humidified incubator (37 °C and 5%
CO2) and used from passages 5 through 10. Cells were seeded on 96 well plates (4,000 cells/
well) and incubated with DMEM supplemented with 10% FBS and 1% Pen-Strep for 24 h.
These cells were treated with Citrate-IONPs (0, 0.002, 0.02, 0.05, 0.1, and 0.2 mg/mL) and
CNA-IONPs (0, 0.2, 0.5, 1, 5, and 10 mg/mL). Citrate-IONP and CNA-IONP concentrations
were based on cytotoxicity observed in preliminary experiments. The cells were incubated
with Citrate-IONPs or CNA-IONPs for 0.5, 3, 6, 12 and 30 h, followed by washing the cells
with PBS three times. After additional 24 h incubation in fresh cell culture media, cell
viability was determined using the resazurin dye assay. Resazurin in PBS was added to the
cell-containing wells to a final concentration of 100 µM. Cell plates were incubated for an
additional 3 h as non-fluorescent resazurin was converted to fluorescent resorufin by live
cells (50, 51). Resorufin signals were measured at λex 485 nm and λem530 nm. Cell viability
was reported as % of control at the same time.
Magnetic resonance imaging
Citrate-IONPs and CNA-IONPs were dispersed in water, PBS, and cell culture media with
two-fold serial dilutions ranging from 0.02 to 2.5 mg/mL (based on IONP content). Citrate-
IONP and CNA-IONP solutions (150 µL) were placed in a 96 well plate and imaged on a
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3.0 Tesla MR imager (Siemens Tim Trio, Erlangen, Germany) using a 10 cm diameter
surface coil to enhance the received signal. Multiple, T2-weighted fast spin echo images of
all samples were acquired with different echo time (TE), to visualize the dependence of the
T2 relaxation time on the particle composition and dispersing media. From the multi echo
T2 images acquired at different echo times, we used a custom-developed software code to
derive T2 on a pixel-by-pixel basis. From these images we estimated the average T2 within
the wells of CNA-IONPs in the three media as a function of particle concentration.
Evaluation of AMF-induced heating profiles and particle stability after AMF exposure
The heating profiles of CNA-IONPs were evaluated in cell culture media (1, 2.5, and 5
mg/mL) under AMF induced by a Taylor Winfield induction power supply (Taylor-Winfield
Technologies MMF-3-135/400-2, Columbus, OH, USA) equipped with a 15 mm diameter, 5
turn solenoid. The AMF field parameters were set to 59.3 kA/m at 300 kHz for 30 minutes.
The temperature of the medium was measured every 0.25 seconds for 30 minutes using a
Fluoroptic® thermometer (LumaSense Technologies, Santa Clara, CA, USA). The initial
medium temperature was 37 °C. The CNA-IONP particle stability was monitored in cell
culture media (1, 2.5, and 5 mg/mL) for 30 h after 30 min AMF using DLS.
Statistical analysis
One-way ANOVA followed by Tukey’s test was used to test for significant differences
among particle sizes of the samples with different incubation times and temperatures. Two-
way ANOVA followed by Bonferroni multiple comparisons was used to test for significant
differences among different concentration groups and times (GraphPad Prism Version 3.00
for Windows, GraphPad Software, San Diego, CA). Statistical significance was accepted at
a level of p < 0.05. All results are reported as mean ± standard deviation (SD).
RESULTS AND DISCUSSION
Preparation and characterization of Citrate-IONPs and CNA-IONPs
GPC analyses confirmed that CNAs were successfully formed with narrow dispersity
(Figure 3). Molecular weight of CNAs was 304,007 Da, indicating that approximately 32
PEG-p(Asp) block copolymer chains formed an individual CNA particle. No free PEG-
p(Asp) block copolymers (Mn = 9,600 Da) were seen after CNA synthesis, although small
molecular weight impurities (Mn = 2,859 Da) were observed. The particle size of empty
CNAs was 36 ± 5 nm. These results were consistent with our previous observations for other
CNAs (46, 47). The solution containing IONPs formed dark brown precipitates immediately
after NH4OH was added in the presence of either citric acid or empty CNAs. In comparison
to Citrate-IONPs, CNA-IONPs remained soluble in aqueous solutions even after
centrifugation. As a result, unreacted iron ions, aggregated IONPs, and other impurities were
readily removed from CNA-IONPs. Subsequent DLS measurements showed that CNA-
IONPs were 25 ± 3 nm, similar to empty CNAs, indicating that the cross-linked core of
CNAs effectively suppressed the growth of IONPs inside the nanoassemblies, preventing
aggregation. Citrate-IONPs were initially 90 ± 10 nm in water at 200 µg/mL, but their
particle sizes varied as agglomeration and precipitation occurred (discussed in detail in
Particle stability section). CNA-IONPs showed 25 ± 3 and 25 ± 1 % (wt%) IONP loading,
Dan et al. Page 6
Pharm Res. Author manuscript; available in PMC 2014 July 01.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
determined by TGA and ICP-MS analyses, respectively. Zeta potentials of Citrate-IONPs
and CNA-IONPs in PBS at pH 7.4 were −29.5 ± 3.6 and −5.0 ± 0.6 mV, respectively. These
results suggested that CNA-IONPs effectively protected IONPs inside the carboxyl-rich
nanoassembly core, shielding the electric charge of IONP chelates with CNAs.
Particle stability
Citrate-IONPs and CNA-IONPs were first dispersed in water, PBS, and cell culture media at
0.1 mg/mL for solubility testing (Figure 4). Citrate-IONPs dispersed partially in aqueous
solutions, but the solutions were turbid (Figure 4A), forming precipitates (Figure 4B, blue
box). On the other hand, CNA-IONPs were stable in all aqueous solutions: the letters ‘IO’
can be seen clearly through the brown solution in Figure 4A and no precipitates are seen in
Figure 4B (red box). Interestingly, Citrate-IONPs remained at around 400 nm in the serum-
containing cell culture medium at 37 °C for 3 h, but they ultimately precipitated in water,
PBS, and DMEM (Figure 5A). It is surmised that Citrate-IONPs in the cell culture medium
might have bound to bovine serum albumin (BSA) from 10% FBS, forming 400 nm
complexes that dispersed in the solution as previous studies reported that BSA stabilized
metal oxide nanoparticles (52–54). Nevertheless, rapid agglomeration in the cell culture
medium to > 400 nm will still likely limit biomedical applications of Citrate-IONPs.
Previous research demonstrated that IONPs smaller than 50 nm had a longer circulation time
in blood than larger IONPs that were rapidly cleared by the MPS (55).
CNA-IONPs were stable in water and cell culture media at 22, 37, and 43 °C for 30 h, and
particle size remained unchanged between 25 ~ 29 nm in diameter (Figures 5A and 5B).
There were no significant changes in the particle size of CNA-IONP from 1 to 5 mg/ml
(Figure 5C). A previous study showed that the magnetic property of IONPs is size-
dependent and that the particle size is linearly correlated with the saturation magnetization
of IONPs (56). As mentioned above, IONPs below 50 nm can circumvent the MPS and have
a longer circulation time (55). Several researchers demonstrated plasma proteins rapidly
bound to nanoparticle surfaces, forming a protein corona which can change nanomaterial
physicochemical properties and influence their fate in vivo (57–59). In this study, the
presence of 10% FBS in cell culture medium produced no significant change in the particle
size of CNA-IONPs over 30 h in a biologically-relevant medium compared with their size in
water. In general, the small particle size that remained constant for > 30 h is favorable for in
vivo applications using CNA-IONPs because particle size-induced changes in IONPs
magnetic properties and biodistribution will be minimal. Therefore, these results suggested
that CNA-IONPs would be stable in blood in vivo, which will be beneficial especially for
increasing their blood retention time, and thus potentially improving blood-tumor barrier
penetration for diagnosis and therapy of tumors located away from the body surface such as
brain (60).
Cytotoxicity of Citrate-IONPs and CNA-IONPs
Time-dependent cytotoxicity of Citrate-IONPs and CNA-IONPs was tested in a murine
brain endothelial cell line (bEnd.3) as shown in Figure 6. Citrate-IONPs caused a significant
decrease in cell viability at concentrations greater than 0.05 mg/mL, and cell viability
dropped rapidly at 0.1 mg/mL after 3 h (Figure 6A). This is consistent with previous reports
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showing IONPs caused serious cytotoxicity in cells, limiting their applications as imaging
contrast agents (23), and significantly increased reactive oxygen species (> 0.025 mg/mL)
(61). Even FDA-approved MRI contrast agents, such as Endorem® and Sinerem®
(derivatized dextran coated IONPs), are reported to cause cell growth inhibition over a 24 h
period at 0.05 mg/mL (62), similar to the Citrate-IONPs cytotoxic concentration in this
study. Previous studies showed that IONP toxicity in vitro was highly dependent on size,
surface modification, charge, and cell type (63). However, most IONPs started to show
toxicity above 1 mg/mL in vitro despite their size, surface modification, charge, or the cell
type (23). On the contrary, CNA-IONPs caused no cell death up to 10 mg/mL and 30 h
exposure (Figure 6B). These results demonstrate that CNA-IONPs significantly improved
biocompatibility of IONPs entrapped inside the nanoassemblies as opposed to citrate-IONP
formulations.
MRI of Citrate-IONPs and CNA-IONPs
Citrate-IONPs and CNA-IONPs showed concentration-dependent changes on T2-weighted
MR images (image darkening) (Figure 7). Citrate-IONPs showed contrast patterns similar to
CNA-IONPs in water, but Citrate-IONPs dispersed initially yet agglomerated gradually in
PBS and cell culture media, forming agglomerates on the bottom of wells when placed in
the magnetic field of the MR imager. Images acquired transverse to the wells showed that
Citrate-IONPs precipitated at the bottom of wells producing zones of intense signal loss on
T2 images (side-view images in Figure 7). Citrate-IONPs showed a dark signal on the T2
images above 0.16 mg/mL in water. Citrate-IONPs were observed to agglomerate faster in
cell culture medium than PBS at the same concentration (data not shown), and showed dark
images above 0.63 mg/mL.
On the contrary, CNA-IONPs were stable in water, PBS and cell culture media (Figure 4B,
red box), showing concentration-dependent T2-weighted MRI contrast (Figure 7). CNA-
IONPs produced dark MR images as low as 0.04 mg/mL in water and 0.02 mg/mL in cell
culture medium. CNA-IONPs evenly distributed in the solution and produced homogenous
MR images. The average T2 within the wells of CNA-IONPs in water, PBS and cell culture
medium as a function of their concentration were estimated from these images. Plots of
relaxation rate (i.e. 1/T2) versus CNA-IONP concentration showed a linear dependency with
correlation coefficients nearly 1 in all three media (data not shown). From the slope of 1/T2
vs particle concentration curves, we estimated CNA-IONP relaxivities to be 70, 63 and
73/s/mM Fe in water, PBS and cell culture medium, respectively. Previous research showed
that IONPs have T2 relaxivities around 30 /s/mM Fe (18, 43, 64). Contrast efficiency was
considerably enhanced by CNA-IONPs compared with Citrate-IONPs. We tried to estimate
relaxivities for the T2* relaxation rates (1/T2*, s−1) measurements in a similar way.
However, the T2* was so low for the samples that the measurements were not reliable.
Nevertheless, the ratio of T2* relaxivity and T2 relaxivity (R2*/R2, mM−1s−1) would be
high, indicating the potential of the CNA-IONPs to strongly influence the contrast on either
T2* or T2 weighted MRI. Previous clinical investigation showed that IONPs with diameters
less than 40 nm can accumulate at the margins of human brain tumors resulting in
improvement of their delineation on MRI (16). Therefore, CNA-IONPs are expected to
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significantly improve contrast efficiency and serve as excellent T2 contrast agents in future
in vivo applications.
AMF-induced heating profiles and particle stability after AMF exposure
Another exciting application of IONPs is AMF-mediated remote heating hyperthermia.
CNA-IONPs in cell culture media generated heat in response to AMF, increasing the
solution temperature in a concentration-dependent manner (Figure 8). The solution
temperature reached equilibrium in 10 min at 40, 41 and 42 °C with 1, 2.5 and 5 mg/mL
CNA-IONPs, respectively. This temperature range is promising because previous results
demonstrated that cancer cells were susceptible to > 40 °C and IONP-induced local
hyperthermia appeared effective to kill glioma T-9 cells in Fisher F344 rats (7, 11). CNA-
IONPs in cell culture media exposed to AMF for 30 min were subsequently incubated for 30
h at 37 °C, yet the AMF caused no adverse changes in particle sizes of CNA-IONPs (Figure
5C). Although no large aggregates were formed, the particle sizes of CNA-IONPs increased
slightly at 2.5 and 5 mg/mL, following 30 minute AMF exposure and subsequent 30 h at 37
°C. Such an increase was not shown in 1 mg/mL CNA-IONPs. We found that the particle
sizes were consistent for all 1 mg/mL CNA-IONPs incubated at 22, 37, and 43 °C for 30 h
continuously or after 30 min AMF exposure. These results suggested that the increase in
particle sizes of 2.5 and 5 mg/mL CNA-IONPs following 30 min AMF exposure might be
attributed not to interparticular aggregates during AMF-induced heat generation but to
molecular vibration of IONPs entrapped in CNAs, causing relaxation and rearrangement of
block copolymer segments in the CNA core. Despite the slight increase in the particle size,
CNA-IONPs were always smaller than 40 nm after 30 h at 37 °C in cell culture media
regardless of AMF exposure, indicating that IONPs can remain entrapped stably inside
CNAs without compromising AMF-responsive magnetic properties. These results suggested
that CNA-IONPs would be a promising nanoscale tool to achieve localized hyperthermia in
vivo, an elegant thermal therapy that invokes little damage to critical organs or tissues such
as the central nervous system compared with whole body hyperthermia, which often leads to
potential toxicities to the brain (65), or to develop a multifunctional nanoparticle for
theranostic applications by delivering IONPs in combination with various therapeutic agents
(9, 14).
CONCLUSIONS
CNA-IONPs, block copolymer cross-linked nanoassemblies entrapping superparamagnetic
Fe3O4 iron oxide in a cross-linked core, showed controlled particle size in biological
conditions and less toxicity without loss of magnetic properties in comparison to Citrate-
IONPs, conventional iron oxide formulations stabilized with citric acid. CNA-IONPs did not
agglomerate in water, PBS, or cell culture media, maintaining a clinically-relevant particle
size (< 40 nm), suggesting that such stable and small CNA-IONPs may achieve preferential
accumulation in tumors and reduced macrophage uptake in vivo. Cytotoxicity of CNA-
IONPs was significantly lower than that of Citrate-IONPs, causing no cell death up to 10
mg/mL using a murine brain endothelial cell line (bEnd.3). For MRI contrast agent
application, CNA-IONPs showed concentration-dependent T2-weighted MRIs with
correlation coefficients nearly 1 between CNA-IONP concentrations and T2-weighted
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MRIs. CNA-IONPs considerably enhanced the T2 relaxivities compared to Citrate-IONPs.
CNA-IONPs retained the magnetic properties of IONPs, which generated heat at mild
hyperthermic temperatures (40 ~ 42°C) in the presence of AMF. In conclusion, CNA-IONPs
significantly improved particle stability and biocompatibility of IONPs, and thus provide a
promising iron oxide nanoparticle formulation for MRI and AMF-induced remote
hyperthermia with low toxicity and high efficiency.
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Figure 1.
Citrate-coated iron oxide nanoparticles (Citrate-IONPs) and cross-linked nanoassemblies
entrapping IONPs (CNA-IONPs). (A: A chelate is formed between citric acid and Fe3O4
iron oxide; B: CNA-IONPs entrap Fe3O4 in the core to protect the iron oxide from
agglomeration and protein binding; and C: Fe3O4 IONPs are stabilized in the cross-linked
core of CNAs.)
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Figure 2.
Synthesis schemes for empty CNAs (A), Citrate-IONPs (B), and CNA-IONPs (C).
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Figure 3.
Gel permeation chromatography (GPC) spectra of CNAs.
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Figure 4.
Citrate-IONPs and CNA-IONPs in aqueous solutions. (A: Turbidity of sample solutions at
0.1 mg/mL; and B: Enlarged images of the bottom of a 1.5 mL glass vial showing
precipitates of Citrate-IONPs [blue box] but not CNA-IONPs [red box])
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Figure 5.
Particle stability characterization results. Samples were incubated in DMEM cell culture
media with 10% FBS. (A: Time-dependent changes of particle sizes for Citrate-IONPs
[circles] and CNA-IONPs [squares] incubated at room temperature. The asterisk (*)
indicates that Citrate-IONPs started precipitating; B: Temperature effects on particle sizes
for CNA-IONPs incubated for 30 h; and C: Concentration effects on particle sizes of CNA-
IONPs following 30 min AMF)
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Figure 6.
Biocompatibility characterization results. A mouse brain endothelial cell line (bEnd.3) was
incubated with either Citrate-IONPs (A) or CNA-IONPs (B) at different concentrations and
times. The asterisks (*) indicate significant differences (p < 0.05) from the three lower
concentrations (0.002, 0.02, and 0.05 mg/mL).
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Figure 7.
Visual images and T2-weighted MRI of Citrate-IONPs and CNA-IONPs. Serial dilutions of
the samples were prepared on a 96-well plate, containing water, PBS, and DMEM with 10%
FBS. Side view images of transverse plane MRIs show dispersion and precipitation of the
Citrate-IONPs and lack of CNA-IONP precipitation in DMEM with 10% FBS.
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Figure 8.
Heating profiles of CNA-IONPs in the presence of AMF. Three concentrations (1, 2.5, and 5
mg/mL) were tested for fine-tuned remote heating with 30 minute applications of AMF.
Control indicates the initial temperature of cell culture medium containing no CNA-IONPs
(37 °C).
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